Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
by Zacks Equity Research
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm
by Zacks Equity Research
Medtronic (MDT) focuses on initiatives to boost its diabetes business.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
BMY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. NVO: Which Stock Is the Better Value Option?
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label
by Zacks Equity Research
Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.
LLY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
LLY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk (NVO) Announces Results in Diabetes Studies
by Zacks Equity Research
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
by Zacks Equity Research
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
LLY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk's Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
Top Research Reports for Walmart, AT&T & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AT&T (T) and Novo Nordisk (NVO).
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Novo Nordisk Obtains Licence for Sickle Cell Disease Program
by Zacks Equity Research
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Novo Nordisk Poised on Strong Pipeline Amid Competition
by Zacks Equity Research
Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
by Zacks Equity Research
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP
by Zacks Equity Research
CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm
by Zacks Equity Research
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Eurozone Beats United States Again: 5 Hot Stock Picks
by Zacks Equity Research
5 Europe-based stocks to buy as the region scores decade-high growth rate in 2017.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal